Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Key Inclusion Criteria: * Statin intolerant and statin tolerant * Fasting LDL-C between 130 mg/dL and 220 mg/dL * Fasting triglyceride less than or equal to 400 mg/dL * Body mass index (BMI) between 18 and 45 kg/m2 Key Exclusion Criteria: * History or current clinically significant cardiovascular disease * History or current type 1 diabetes or uncontrolled type 2 diabetes * Use of metformin or thiazolidinediones (TZD) within 3 months of screening * History of joint symptoms difficult to differentiate from myalgia * Uncontrolled hypothyroidism * Liver disease or dysfunction * Renal dysfunction or nephritic syndrome * Gastrointestinal (GI) conditions or prior GI procedures * HIV or AIDS * History or malignancy * History or drug or alcohol abuse within last 2 years * Use of experimental or investigational drugs within 30 days of screening * Use of ETC-1002 in a previous clinical study